Effects of maternal intake of n-3 fatty acids on lipid profile and leptin concentration in cord blood

Batirel, Saime; Büyükuslu, Nihal; Bekiroğlu, Nural; Garipağaoğlu, Muazzez

doi:10.5472/marumj.357250

Cited by 1 publication

(2 citation statements)

References 31 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…To our knowledge, there have been only two randomized controlled trials evaluating whether n-3 LCPUFAs supplementation alters neonatal leptin and/or adiponectin levels, and both were conducted in healthy pregnant women ( 25 , 26 ). Batirel et al ( 25 ) studied pregnant women with n-3 LCPUFAs daily supplementation [eicosapentaenoic acid (EPA) 504 mg + DHA 378 mg; n = 13] and controls (without supplementation, n = 18) from 22 to 24 weeks of gestation to delivery, and reported no effect on cord blood leptin. England et al ( 26 ) studied pregnant women with DHA-rich fish oil supplementation (containing 90 mg DHA, n = 37) or soy oil (placebo controls, n = 41) from 12 to 20 weeks gestation until delivery, and reported no alterations in cord blood leptin and adiponectin concentrations.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers

Wang

Zhang

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

Background and objectiveGestational diabetes mellitus (GDM) “programs” an elevated risk of metabolic dysfunctional disorders in the offspring, and has been associated with elevated leptin and decreased adiponectin levels in cord blood. We sought to assess whether docosahexaenoic acid (DHA) supplementation in GDM affects neonatal metabolic health biomarkers especially leptin and adiponectin.MethodsIn a randomized controlled trial, singleton pregnant women with de novo diagnosis of GDM at 24–28 weeks of gestation were randomized to dietary supplementation of 500 mg DHA per day (intervention, n = 30) until delivery or standard care (control, n = 38). The primary outcomes were cord blood leptin and total adiponectin concentrations. Secondary outcomes included high-molecular-weight (HMW) adiponectin and insulin-like growth factor-1 (IGF-1) concentrations in cord blood, maternal glycemic control post-intervention and birth weight (z score). In parallel, 38 euglycemic pregnant women were recruited for comparisons of cord blood biomarkers.ResultsThere were no significant differences in cord serum leptin, total and HMW adiponectin and IGF-1 concentrations between DHA supplementation and control groups (all p > 0.05). Maternal fasting and 2-h postprandial blood glucose levels at 12–16 weeks post-intervention were similar between the two groups. The newborns in the DHA group had higher birth weight z scores (p = 0.02). Cord blood total and HMW adiponectin concentrations were significantly lower in GDM vs. euglycemic pregnancies.ConclusionDocosahexaenoic acid supplementation at 500 mg/day in GDM women did not affect neonatal metabolic biomarkers including leptin, adiponectin and IGF-1. The results are reassuring in light of the absence of influence on neonatal adipokines (leptin and adiponectin), and potential benefits to fetal growth and development.Clinical Trial Registration: Clinicaltrials.gov, NCT03569501.

show abstract

Section: Discussionmentioning

confidence: 99%